Skip to main content

Advertisement

SpringerLink
Log in

Elevation of PRKCDBP, A Novel Transcriptional Target of TNF-α, and Its Downregulation by Infliximab in Patients with Ulcerative Colitis

  • Original Article
  • Published:
Digestive Diseases and Sciences Aims and scope Submit manuscript

Abstract

Background

Protein kinase C delta binding protein (PRKCDBP/Cavin3/hSRBC) is a putative tumor suppressor that is downregulated in many human cancers. Recently, PRKCDBP was identified to be activated by nuclear factor-κB in response to tumor necrosis factor (TNF)-α.

Aims

To explore the potential of PRKCDBP as a diagnostic or prognostic marker for inflammatory bowel disease, the possible correlation between its expression status and TNF-α signaling was evaluated in ulcerative colitis (UC) patients, both pre- and post-infliximab (IFX) therapy.

Methods

In total, 31 IFX therapy-naïve patients (13 females; median age, 41 years) with moderate-to-severe UC who had been scheduled for IFX treatment were included. Immunohistochemical analysis of TNF-α and PRKCDBP expression was performed in rectal biopsies.

Results

A significant correlation was observed in immunoreactivity between TNF-α and PRKCDBP. IFX therapy reduced immunohistochemical expression of PRKCDBP and TNF-α (P < 0.001 and P = 0.005, respectively). The mean PRKCDBP expression level decreased from 54.5 to 30.2 %, and that of TNF-α decreased from 54.5 to 36.2 %. The immunohistochemical expression pre- and post-PRKCDBP therapy correlated significantly with TNF-α levels pre- and post-therapy (Spearman’s rank correlation test; P = 0.005 and P = 0.001, respectively).

Conclusions

These results demonstrate that mucosal expression of PRKCDBP correlated strongly with TNF-α expression in UC patients and that IFX therapy resulted in profound reductions in both PRKCDBP and TNF-α. Thus, these findings support that PRKCDBP expression is tightly controlled by TNF-α, and the anti-inflammatory effect of IFX may in part stem from blockade of the TNF-α-PRKCDBP signaling pathway.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

Similar content being viewed by others

References

  1. Danese S, Fiocchi C. Ulcerative colitis. N Engl J Med. 2011;365:1713–1725.

    Article  CAS  PubMed  Google Scholar 

  2. Hanauer SB. Medical therapy for ulcerative colitis 2004. Gastroenterology. 2004;126:1582–1592.

    Article  PubMed  Google Scholar 

  3. Lichtenstein GR, Rutgeerts P. Importance of mucosal healing in ulcerative colitis. Inflamm Bowel Dis. 2010;16:338–346.

    Article  PubMed  Google Scholar 

  4. Neurath MF, Travis SP. Mucosal healing in inflammatory bowel diseases: a systematic review. Gut. 2012;61:1619–1635.

    Article  CAS  PubMed  Google Scholar 

  5. Pineton de Chambrun G, Peyrin-Biroulet L, Lemann M, Colombel JF. Clinical implications of mucosal healing for the management of IBD. Nat Rev Gastroenterol Hepatol. 2010;7:15–29.

    Article  PubMed  Google Scholar 

  6. Fiorino G, Cesarini M, Indriolo A, Malesci A. Mucosal healing in ulcerative colitis: where do we stand? Curr Drug Targets. 2011;12:1417–1423.

    Article  CAS  PubMed  Google Scholar 

  7. Wright R, Truelove SR. Serial rectal biopsy in ulcerative colitis during the course of a controlled therapeutic trial of various diets. Am J Dig Dis. 1966;11:847–857.

    Article  CAS  PubMed  Google Scholar 

  8. Sipponen T, Karkkainen P, Savilahti E, et al. Correlation of faecal calprotectin and lactoferrin with an endoscopic score for Crohn’s disease and histological findings. Aliment Pharmacol Ther. 2008;28:1221–1229.

    Article  CAS  PubMed  Google Scholar 

  9. Hanai H, Takeuchi K, Iida T, et al. Relationship between fecal calprotectin, intestinal inflammation, and peripheral blood neutrophils in patients with active ulcerative colitis. Dig Dis Sci. 2004;49:1438–1443.

    Article  PubMed  Google Scholar 

  10. Sipponen T, Savilahti E, Kolho KL, Nuutinen H, Turunen U, Farkkila M. Crohn’s disease activity assessed by fecal calprotectin and lactoferrin: correlation with Crohn’s disease activity index and endoscopic findings. Inflamm Bowel Dis. 2008;14:40–46.

    Article  PubMed  Google Scholar 

  11. Sartor RB. Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:390–407.

    Article  CAS  PubMed  Google Scholar 

  12. Melmed GY, Abreu MT. New insights into the pathogenesis of inflammatory bowel disease. Curr Gastroenterol Rep. 2004;6:474–481.

    Article  PubMed  Google Scholar 

  13. Olsen T, Goll R, Cui G, et al. Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis. Scand J Gastroenterol. 2007;42:1312–1320.

    Article  CAS  PubMed  Google Scholar 

  14. Olsen T, Cui G, Goll R, Husebekk A, Florholmen J. Infliximab therapy decreases the levels of TNF-alpha and IFN-gamma mRNA in colonic mucosa of ulcerative colitis. Scand J Gastroenterol. 2009;44:727–735.

    Article  CAS  PubMed  Google Scholar 

  15. Hassan C, Ierardi E, Burattini O, et al. Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab. Dig Liver Dis. 2007;39:811–817.

    Article  CAS  PubMed  Google Scholar 

  16. Arijs I, Li K, Toedter G, et al. Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis. Gut. 2009;58:1612–1619.

    Article  CAS  PubMed  Google Scholar 

  17. Olsen T, Goll R, Cui G, Christiansen I, Florholmen J. TNF-alpha gene expression in colorectal mucosa as a predictor of remission after induction therapy with infliximab in ulcerative colitis. Cytokine. 2009;46:222–227.

    Article  CAS  PubMed  Google Scholar 

  18. Xu XL, Wu LC, Du F, et al. Inactivation of human SRBC, located within the 11p15.5-p15.4 tumor suppressor region, in breast and lung cancers. Cancer Res. 2001;61:7943–7949.

    CAS  PubMed  Google Scholar 

  19. Lee JH, Byun DS, Lee MG, et al. Frequent epigenetic inactivation of hSRBC in gastric cancer and its implication in attenuated p53 response to stresses. Int J Cancer. 2008;122:1573–1584.

    Article  CAS  PubMed  Google Scholar 

  20. Zochbauer-Muller S, Fong KM, Geradts J, et al. Expression of the candidate tumor suppressor gene hSRBC is frequently lost in primary lung cancers with and without DNA methylation. Oncogene. 2005;24:6249–6255.

    Article  PubMed  Google Scholar 

  21. Tong SY, Lee JM, Ki KD, Seol HJ, Choi YJ, Lee SK. Genetic polymorphism of PRKCDBP is associated with an increased risk of endometrial cancer. Cancer Invest. 2012;30:642–645.

    Article  CAS  PubMed  Google Scholar 

  22. Lee JH, Kang MJ, Han HY, et al. Epigenetic alteration of PRKCDBP in colorectal cancers and its implication in tumor cell resistance to TNFalpha-induced apoptosis. Clin Cancer Res. 2011;17:7551–7562.

    Article  CAS  PubMed  Google Scholar 

  23. Blam ME, Stein RB, Lichtenstein GR. Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives. Am J Gastroenterol. 2001;96:1977–1997.

    CAS  PubMed  Google Scholar 

  24. Sutherland LR, Martin F, Greer S, et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis, and proctitis. Gastroenterology. 1987;92:1894–1898.

    CAS  PubMed  Google Scholar 

  25. Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology. 2004;126:1518–1532.

    Article  PubMed  Google Scholar 

  26. Ooi CJ, Fock KM, Makharia GK, et al. The Asia-Pacific consensus on ulcerative colitis. J Gastroenterol Hepatol. 2010;25:453–468.

    Article  CAS  PubMed  Google Scholar 

  27. Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol. 2005;19:5A–36A.

    PubMed  Google Scholar 

  28. Schmidt C, Giese T, Hermann E, Zeuzem S, Meuer SC, Stallmach A. Predictive value of mucosal TNF-alpha transcripts in steroid-refractory Crohn’s disease patients receiving intensive immunosuppressive therapy. Inflamm Bowel Dis. 2007;13:65–70.

    Article  PubMed  Google Scholar 

  29. Rismo R, Olsen T, Cui G, Christiansen I, Florholmen J, Goll R. Mucosal cytokine gene expression profiles as biomarkers of response to infliximab in ulcerative colitis. Scand J Gastroenterol. 2012;47:538–547.

    Article  CAS  PubMed  Google Scholar 

  30. Ferrante M, Vermeire S, Katsanos KH, et al. Predictors of early response to infliximab in patients with ulcerative colitis. Inflamm Bowel Dis. 2007;13:123–128.

    Article  PubMed  Google Scholar 

  31. Oussalah A, Evesque L, Laharie D, et al. A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization. Am J Gastroenterol. 2010;105:2617–2625.

    Article  CAS  PubMed  Google Scholar 

  32. Olsen T, Rismo R, Cui G, Goll R, Christiansen I, Florholmen J. TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation. Cytokine. 2011;56:633–640.

    Article  CAS  PubMed  Google Scholar 

  33. Ing NH. Steroid hormones regulate gene expression posttranscriptionally by altering the stabilities of messenger RNAs. Biol Reprod. 2005;72:1290–1296.

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors report no conflict of interests.

Author information

Authors and Affiliations

  1. Division of Gastroenterology, Department of Internal Medicine, Kyung Hee University School of Medicine, 23 Kyungheedae-ro, Dongdaemun-gu, Seoul, 130-872, Republic of Korea

    Jung-Wook Kim, Hyo Jong Kim, Chang Kyun Lee, Jae-Jun Shim, Jae Young Jang, Suk Ho Dong, Byung-Ho Kim & Young Woon Chang

  2. School of Life Sciences and Biotechnology, Korea University, Seoul, Republic of Korea

    Sung-Gil Chi

Authors
  1. Jung-Wook Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hyo Jong Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chang Kyun Lee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Jae-Jun Shim
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jae Young Jang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Suk Ho Dong
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Byung-Ho Kim
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Young Woon Chang
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Sung-Gil Chi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hyo Jong Kim.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kim, JW., Kim, H.J., Lee, C.K. et al. Elevation of PRKCDBP, A Novel Transcriptional Target of TNF-α, and Its Downregulation by Infliximab in Patients with Ulcerative Colitis. Dig Dis Sci 59, 2947–2957 (2014). https://doi.org/10.1007/s10620-014-3282-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-014-3282-4

Keywords

Search

Navigation